4 курс / Лучевая диагностика / Позитронно_эмиссионная_томография_в_клинической_практике_Рудас_М

19.Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 29:69-79; 1999.

20.Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors//J Nucl Med 44:1301–1314; 2003.

21.Di Chiro G, DeLaPaz RL, Brooks R, et al. Glucose utilization of cerebral gliomas measured by (18F)fluorodeoxyglucose and positron emission tomography//Neurology 32:1323-1329; 1982.

22.Diehl M, Risse JH, Brandt-Mainz K et al. 18F-FDG PET in medullary thyroid cancer: results of a multicenter study//Eur J Nucl Med 28:1671-1676; 2001.

23.Dizendorf E, von Schulthess G, Hany T. Application of oral contrast media in co-registered PET-CT imaging//Am J Roentgenol 179:477-481; 2002.

24.Duncan, JS. Imaging and epilepsy//Brain 120:339-377; 1997.

25.Engel J, Kuhl DE, Phelps ME. Patterns of human local cerebral glucose metabolism during epileptic seizures//Science 218:64-66; 1982.

26.Fishbein NJ, Assar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F- FDG in detecting residual/recurrent squamous cell carcinoma of the head and neck//Am J Neuroradiol 19:1189-1196; 1998.

27.Flamen P, Lerut A, Van Cutsem E, et al. Utility of PET for the staging of patients with potentially operable esophageal carcinoma//J Clin Oncol 18:3202-3210; 2000.

28.Frackowiak RSJ, Pozzilli C, Legg NI, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography//Brain 104:753-778; 1981.

29.Henry TR, Berkovic SF, Duncan JS (eds): Functional Imaging in the Epilepsies. Philadelphia, Lippincott Williams & Wilkins, 2000.

30.Henry TR, Van Heertum RL. Positron emission tomography and single photon emission computed tomography in epilepsy care//Seminars in Nuclear Medicine 33:88-104; 2003.

31.Herholz K. Hölzer T. Bauer B. 11C-methionine PET for differential diagnosis of low-grade gliomas// Neurology 50(5):1316-22; 1998.

32.Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body PET in the treatment of Hodgkin disease//Cancer 91:302-310; 2001.

33.Iglesias S, Marchal G, Rioux P, et al. Do changes in oxygen metabolism in the unaffected cerebral hemisphere underlie early neurological recovery after stroke? A positron emission tomography study//Stroke 27:1192-1199; 1996.

34.Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec)//Med Klin 97(suppl 1):28-30; 2002.

35.Kamel E, Burger WGC, von Schulthess G, et al. Detection of recurrent laryngeal nerve palsy in patients with lung cancer using PET-CT image fusion//Radiology 38:153-158; 2002.

36.Khan MA, Combs CS, Brunt EM, et al. PET scanning in the evaluation of hepatocellular carcinoma// J Hepatol 32:792-797; 2000.

37.Kubik-Huch RA, Dorffler W, von Schulthess G, et al. Value of 18F-FDG PET , CT and MRI in diagnosing primary and recurrent ovarian carcinoma//Eur Radiol 10:761-767; 2000.

38.Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and

18F-FDG//Radiology 197:205-211; 2002.

39.Lassen NA, Lenzi GL, Fieschi C. Ischemic penumbra and neuronal death: comments on the therapeutic window in acute stroke with particular reference to thrombolytic theraphy//Cerebrovasc. Dis. 1:32-35; 1991.

40.Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy//Ann Surg 232:743-752; 2000.

41.Mikhaeel NG, Timothy AR, Hain SF, et al. 18F-FDG PET for the assessment of residual masses on CT following treatment of lymphomas//Ann Oncol 11:147-150; 2000.

42.Mineura K, Sasajima T, Kowada M, et al. Early delineation of cerebral glioma using amino acid positron tracers//Comput Med Imaging Graph 21:63-66; 1997.

43.Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer//J Clin Oncol 19:2707-2803; 2001.

44.Nestle U, Walter K, Schmidt S, et al. 18F-FDG PET for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis//Int J Radiat Oncol Biol Phys 44:593-597; 1999.

45.Nitzsche EU, Hoegerle S, Mix M, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?//Eur J Nucl Med Mol Imaging 25:1238-1243; 2002.

46.Nuutinen J, Sonninen P, Lehikoinen P, et al.Radiotherapy treatment planning and long-term followup with [(11)C] methionine PET in patients with low-grade astrocytoma//Int J Radiat Oncol Biol Phys 48(1):43-52; 2000.

47.Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of 18F-fluorodeoxyglucose and L-methyl-11C-methionine//Am J Neuroradiol 17(2): 345-53; 1996.

48.Pacard RC, Ham LP. Promising techniques in the assesment of mild head injury//Seminars in Neurology 14:74-83; 1994.

49.Pantano P, Formisano R, Ricci M, et al. Motor recovery after stroke. Morphological and functional brain alterations//Brain 119: 1849-1857; 1996.

50.Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future//Radiology 226:315–336; 2003.

51.Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with PET//N Engl J Med 343:254-261; 2000.

52.Rohren EM, Provenzale JM, Barboriak DP, et al. Screening for cerebral metastases with FDG PET in patients undergoing whole body staging of non-central nervous system malignancy//Radiology 226:181-187; 2003.

53.Ruff RM, Crouch JA, Troster AI, et al. Selected cases of poor outcome following a minor brain trauma: comparing neuropsychological and positron emission tomography assessment//Brain Injury 8:297-308; 1994.

54.Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET//J Nucl Med 41:1695-1701; 2000.

55.Segall GM. FDG PET imaging in patients with lymphoma:a clinical perspective//J Nucl Med 28:1707-1723; 2001.

56.Serrati C, Marchal G, Rioux P, et al. Contralaleral cerebellar hypometabolism: a predictor for stroke outcome?//J. Neurol. Neurosurg. Psychiatry 57:174-179; 1994.

57.Steinert HC, von Schulthess G, Reuland P, et al. A meta-analysis of the literature for staging of malignant melanoma with whole-body FDG PET//J Nucl Med 42(suppl):307P; 2001.

58.Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI//J Craniomaxillofac Surg 28:319-324; 2000.

59.Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with 18F-FDG in management of recurrent colorectal cancer//Arch Surg 134:503-511; 1999.

60.Von Schulthess G. Clinical molecular anatomic imaging. Lippincot Williams & Wilkins 2003.

61.Vorstrup S, Boysen G, Brun B, et al. Evaluation of the regional cerebral vasodilatory capacity before carotid endartereclomy by the acetazolamide test//Neurological Res 9:10-18; 1987.